Blood-Borne Diseases

The CDC’s Advisory Committee on Immunization Practices has included HEPLISAV-B on its list of recommended products for use to vaccinate adults against hepatitis B.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Treatment-experienced patients still have some good options.

The CDC’s ACIP voted to approve updated adult immunization schedule recommendations for adults aged 19 years or older.

The FDA grants PMA approval for the Aptima HBV Quant Assay for the quantitation of hepatitis B viral load on the Panther system.

The San Diego Board of Supervisors ends the local public health emergency announced in September 2017 for the ongoing hepatitis A outbreak in San Diego.

The opioid epidemic in the United States has led to a sharp increase in hepatitis C cases, and with that, a rise in hospitalizations according to a new report.

A new study confirms the ribavirin steady-state serum levels that correspond to high rates of efficacy and low adverse events.

Health officials across the United States have their hands full as hepatitis A cases continue to spring up.

Leonard Sigal, MD, explains the potential adverse consequences of long-term antibiotic therapy.

We’ve rounded up the 10 biggest infectious disease outbreaks of 2017.

Herewith, 4 New Year’s resolutions for the infectious disease community—at least according to us here on the Public Health Watch.

The American Society of Transplantation has reached a consensus on how the treatment of hepatitis C virus with direct-acting antivirals could enable organ transplantations to HCV-negative recipients.

Forty years after the first Ebola outbreak in the Democratic Republic of Congo, investigators find that a small group of survivors are still producing virus-fighting antibodies.

The results of a new study show that when a best practice advisory (BPA) displayed in the electronic health record of patients in the baby boomer generation, it prompted a 5-fold increase in screening for hepatitis C virus (HCV) in this population.

Hepatitis C is more curable than ever thanks to direct-acting antivirals, and now, a new study shows how expanded access to these drugs through Medicaid is helping more individuals get treated.

Five outbreaks of hepatitis A continue to beat down on several states; can addressing the homelessness crisis prevent future outbreaks from happening?

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A new study examines HCV treatment uptake in HCV patients coinfected with HIV.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Hepatitis A outbreaks have been ravaging 5 US states, leaving health officials scrambling.

A recent study finds that prolonged infusion of antipseudomonal β-lactams in patients with sepsis was associated with significantly less mortality when compared with short-term infusion.

The results of a new study show that patients who are co-infected with the hepatitis C virus (HCV) and HIV can experience cure rates similar to individuals infected with HCV alone when both groups receive direct-acting antiviral drugs.

World Toilet Day, November 9th, is dedicated to promoting awareness and inspiring action against the global sanitation crisis.

A research team has found that an antiviral drug available in Russia and a few other countries shows promising results when it comes to fighting Ebola virus disease.

Researchers are gaining a greater understanding of the role that human genetics plays in determining who contracts tuberculosis as well as how severely it impacts its victims.

As the hepatitis A outbreak in San Diego continues, officials focus their efforts on homeless encamped along the San Diego River. Is the situation improving or getting worse?

The vaccine is the only 2-dose regimen for the prevention of infection by all known subtypes of hepatitis b in adults 18 and older.

Despite the availability of highly active agents against HCV, HIV-infected patients require special considerations for drug interactions when considering treatment options.

Alnylam Pharmaceuticals announces exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNA Interference therapeutics for infectious diseases.